NCT00199888View on ClinicalTrials.gov

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

May 29, 2009

Conditions
Cancer of KidneyKidney CancerRenal CancerNeoplasms, KidneyRenal NeoplasmsRenal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma
Interventions
DRUG

124-Iodine-cG250 (124I-cG250)

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Ludwig Institute for Cancer Research

OTHER